Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 2, 2013, Pages 204-207

  Agbaji, Oche ^a   Thio, Chloe L ^b   Meloni, Seema ^c   Graham, Camilla ^d   Muazu, Mohammed ^a   Nimzing, Ladep ^e   Idoko, John ^a,g   Sankalé, Jean Louis ^c   Ekong, Ernest ^c   Murphy, Robert ^f   Kanki, Phyllis ^c   Hawkins, Claudia ^f  

^a UNIVERSITY OF JOS   (Nigeria)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f NORTHWESTERN UNIVERSITY   (United States)

^g NATIONAL AGENCY FOR THE CONTROL OF AIDS   (Nigeria)

Author keywords

Africa; antiretroviral therapy; hepatitis C; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NIGERIA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; COINFECTION; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; LOGISTIC MODELS; MALE; NEVIRAPINE; NIGERIA; ORGANOPHOSPHORUS COMPOUNDS; RNA, VIRAL; STAVUDINE; ZIDOVUDINE;

EID: 84872854079     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827ce536     Document Type: Article

References (15)

1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(suppl 1):S6-S9. (Pubitemid 43053865)
2. Turner J, Bansi L, Gilson R, et al; UK Collaborative HIV Cohort (UK CHIC) Study. The prevalence of hepatitis C virus (HCV) infection in HIVpositive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat. 2010;17:569-577.
3. Sullivan PS, Hanson DL, Teshale EH, et al. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006;20:1171-1179. (Pubitemid 43786106)
4. Barth RE, Huijgen Q, Taljaard J, et al. Hepatitis B/C and HIV in sub- Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010;14: 1024-1031.
5. Charles C, and the BAN Study Team. Prevalence of hepatitis C virus infection among human immunodeficiency virus Type-1 infected pregnant women in Malawi: the BAN study. Paper presented at: 17th Conference on Retroviruses and opportunistic infections, February, 2010; San Francisco, CA. Oral Presentation # 693.
6. Kirk GD, Ocama P, Stabinski L, et al. High prevalence of seroreactivity to hepatitis C virus without detectable viremia in rural Ugandans. Presented at: 13th International Symposium on Viral Hepatitis and Liver Disease; March 2009; Washington, DC.
7. Otegbayo JA, Taiwo BO, Akingbola TS, et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol. 2008;7:152-156. (Pubitemid 351845527)
8. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002;2:293-302. (Pubitemid 34464740)
9. Moore E, Beadsworth MB, Chaponda M, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect. 2010;61:155-163.
10. Idoko J, Meloni S, Muazu M, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis. 2009;49:1268-1273.
11. Miller MF, Haley C, Koziel MJ, et al. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005;41:713-720. (Pubitemid 41170361)
12. lsa SE, Gwamzhi LN, Akolo C, et al. A prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria. Niger J Med. 2010;19: 279-285.
13. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010;52:1143-1155
14. Jones M, Núñez M. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Curr Opin HIV AIDS. 2011;6:546-552.
15. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44:S132-S139. (Pubitemid 43053889)